In triple-negative breast cancer cell lines, treatment with VDX-111 resulted in a reduction in p-ERK1/2 similar to our canine cell lines, and this reduction in ERK activation was replicated with PRL-3 knockdown [11]. This evidence concerns the gene PTP4A3 and triple-negative breast carcinoma.